Palomino Laboratories (PALX) Common Equity (2022 - 2025)

Palomino Laboratories has disclosed Common Equity across 4 years of filings, most recently posting $8.1 million for Q4 2025.

• In Q4 2025, Common Equity rose 44335.15% year-over-year to $8.1 million; the TTM figure through Dec 2025 stood at $8.1 million (up 44335.15% YoY), while the FY2025 annual figure was $300.0 million, changed 0.0% from the prior year.
• Common Equity came in at $8.1 million for Q4 2025 at Palomino Laboratories, up from $7.3 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $8.1 million in Q4 2025 to a low of -$991653.0 in Q1 2025.
• Average Common Equity over 4 years is $1.3 million, with a median of -$18306.0 recorded in 2023.
• The largest YoY upside for Common Equity was 87763.29% in 2025 against a maximum downside of 42008.41% in 2025.
• Over 4 years, Common Equity stood at -$27804.0 in 2022, then soared by 34.16% to -$18306.0 in 2023, then changed by 0.0% to -$18306.0 in 2024, then surged by 44335.15% to $8.1 million in 2025.
• Per Business Quant data, the three most recent Common Equity figures were $8.1 million in Q4 2025, $7.3 million in Q3 2025, and -$447236.0 in Q2 2025.